Cent Eur J Public Health 2024, 32(Suppl):S104-110 | DOI: 10.21101/cejph.a8398
Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study
- 1 Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic
- 2 Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic
- 3 Department of Radiology, AGEL Hospital, Levoča, Slovak Republic
Objective: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors.
Methods: We conducted a single-centre, descriptive, retrospective study without a comparison group.
Results: Out of 141 patients, 70 (49.7%) required follow-up outpatient care. In the subgroup of 66 (46.8%) hospitalized patients, 28 (19.9%) developed interstitial viral pneumonia, with 6 (4.3%) deaths. Unvaccinated patients had a higher incidence of pneumonia (p = 0.020), and obesity was a significant risk factor for both pneumonia (p = 0.001) and mortality (p = 0.011). Patients over 60 years (p = 0.040) and those with cardiovascular diseases (p = 0.026) also had increased pneumonia risk. Male sex was associated with a higher risk of death (p = 0.020).
Conclusion: Molnupiravir treatment was linked to reduced risks of hospitalization and death, particularly in high-risk patients. Vaccination provided additional protection, and obesity obstructive pulmonary disease and autoimmune diseases were significant risk factors for severe outcomes.
Keywords: molnupiravir, COVID-19, treatment, Slovakia, risk factors, single, centre, study
Received: August 28, 2024; Revised: November 29, 2024; Accepted: November 29, 2024; Published: December 31, 2024 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar;19(3):141-54.
Go to original source...
Go to PubMed...
- Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol. 2023;14:1125246. doi: 10.3389/fimmu.2023.1125246.
Go to original source...
Go to PubMed...
- Maas BM, Strizki J, Miller RR, Kumar S, Brown M, Johnson MG, et al. Molnupiravir: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024 Feb;17(2):e13732. doi: 10.1111/cts.13732.
Go to original source...
Go to PubMed...
- Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022 Feb 10;386(6):509-20.
Go to original source...
Go to PubMed...
- Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023 Jan 28;401(10373):281-93.
Go to original source...
- U. S. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for LAGEVRIO™ (molnupiravir) capsules [Internet]. White Oak: FDA; 2023 [cited 2024 Nov 29]. Available from: https://www.fda.gov/media/155054/download.
- Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557-82.
Go to original source...
Go to PubMed...
- Kabinger F, Stiller C, Schmitzová J, Dienemann C, Kokic G, Hillen HS, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28:740-6.
Go to original source...
Go to PubMed...
- Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat. 2021;31(4):325-37.
Go to original source...
Go to PubMed...
- Paymode DJ, Vasudevan N, Ahmad S, Kadam AL, Cardoso FSP, Burns JM, et al. Toward a practical, two-step process for molnupiravir: direct hydroxamination of cytidine followed by selective esterification. Org Process Res Dev. 2021;25(8):1822-30.
Go to original source...
- Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv [Preprint]. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639.
Go to original source...
Go to PubMed...
- Caraco Y, Crofoot GE, Moncada PA, Galustyan AN, Musungaie DB, Payne B, et al. Phase 2/3 trial of molnupiravir for treatment of covid-19 in nonhospitalized adults. NEJM Evid. 2022 Feb;1(2):EVIDoa2100043. doi: 10.1056/EVIDoa2100043.
Go to original source...
Go to PubMed...
- Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, et al. Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic. Clin Exp Med. 2023 Oct;23(6):2715-23.
Go to original source...
Go to PubMed...
- Wong CKH, Au ICH, Lau KTK, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022 Dec;22(12):1681-93.
Go to original source...
Go to PubMed...
- Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or death in adults with COVID-19: emulation of a randomized target trial using electronic health records. BMJ. 2023 Mar 7:380:e072705. doi: 10.1136/bmj-2022-072705.
Go to original source...
Go to PubMed...
- Sawadogo W, Tsegaye M, Gizaw A, Adera T. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: systematic review and meta-analysis. BMJ Nutr Prev Health. 2022;5(1):10-8.
Go to original source...
Go to PubMed...
- Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020;28(7):1195-9.
Go to original source...
Go to PubMed...
- Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: a systematic review. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):655-9.
Go to original source...
Go to PubMed...
- Silverio A, Di Maio M, Citro R, Esposito L, Iuliano G, Bellino M, et al. Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients. BMC Cardiovasc Disord. 2021 Jan 7;21(1):23. doi: 10.1186/s12872-020-01816-3.
Go to original source...
Go to PubMed...
- Cheng SL, Wang PH, Chang CY, Wang HH, Wang CJ, Chiu KM. The benefits of molnupiravir treatment in healthcare facilities patients with COVID-19. Drug Des Devel Ther. 2023 Jan 19;17:87-92.
Go to original source...
Go to PubMed...
- Arbel R, Wolff Sagy Y, Battat E, Lavie G, Sergienko R, Friger M, et al. Molnupiravir use and severe COVID-19 outcomes during the omicron surge. Res Sq [Preprint]. 2022 Sep 29:rs.3.rs-2115769. doi: 10.21203/rs.3.rs-2115769/v1.
Go to original source...
- Weil C, Bergroth T, Eisenberg A, Whiteside YO, Caraco Y, Tene L, et al. Real-world utilization of molnupiravir during the COVID-19 omicron surge in Israel. Epidemiologia. 2023;4(3):309-21.
Go to original source...
Go to PubMed...
- Kimata M, Watanabe A, Yanagida Y, Kinoshita D, Maekawa S. Safety and effectiveness of molnupiravir (LAGEVRIO®) capsules in Japanese patients with COVID-19: interim report of post-marketing surveillance in Japan. Infect Dis Ther. 2023 Apr;12(4):1119-36.
Go to original source...
Go to PubMed...
- Ohashi H, Hishiki T, Akazawa D, Kim KS, Woo J, Shionoya K, et al. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2. Antiviral Res. 2022 Sep;205:105372. doi: 10.1016/j.antiviral.2022.105372.
Go to original source...
Go to PubMed...
- Rosenke K, Okumura A, Lewis MC, Feldmann F, Meade-White K, Bohler WF, et al. Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model. bioRxiv [Preprint]. 2022 Feb 23:2022.02.22.481491. doi: 10.1101/2022.02.22.481491.
Go to original source...
Go to PubMed...